Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Curaleaf International Limited is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is located in 1 distinct art unit, reflecting a specific technical focus for the company's current patent activity. The case is being reviewed by a distinct examiner, concentrating the entire active workload with one individual. This structure reflects a very focused and streamlined interaction with the patent office during this period.
KIM, DANIELLE A is the busiest examiner for the company, holding the 1 pending office action. With only one pending office action in the portfolio, this examiner is the only one currently reviewing the company's applications. The presence of the 1 distinct art unit and the distinct examiner creates a very streamlined prosecution environment. There is no diversification of examiner risk, as the outcome of the entire active portfolio rests with this individual.
For a practitioner, the Biotechnology & Pharmaceuticals focus requires a strategy tailored to the specific standards of the assigned art unit. Since KIM, DANIELLE A manages the only active case, the applicant should prioritize understanding this examiner's past decisions and preferences. The resolution of the 1 pending office action will define the company's current patent trajectory. This focused environment allows for a dedicated legal effort on a single front rather than managing multiple disparate applications across the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257796 | TOPICAL PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF SYNDROMES ASSOCIATED WITH CHRONIC PELVIC PAIN | KIM, DANIELLE A | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257796 | TOPICAL PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF SYNDROMES ASSOCIATED WITH CHRONIC PELVIC PAIN | KIM, DANIELLE A | 1613 | §103Other | Final Rejection | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCuraleaf International Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Danielle A Kim has the most, with 1 of Curaleaf International Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
